Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TNXP | PRESS-RELEASE | neutral | 2/10 | Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study characterizing fibro | May 14, 2026 |
| HYPD | 8-K | bullish | 7/10 | Hyperion DeFi reported Q1 2026 GAAP net income of $8.8M (vs. Q4 2025 net loss of $39.8M) and record Adjusted EBITDA of $ | May 14, 2026 |
| BIIB | PRESS-RELEASE | mixed | 6/10 | Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary en | May 14, 2026 |
| FENC | PRESS-RELEASE | bullish | 6/10 | Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 per diluted share, ver | May 14, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine reported new preclinical data for EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, | May 14, 2026 |
| LABT | EFFECT | bearish | 5/10 | The SEC declared effective the S-1 registration statement for Lakewood-Amedex (LABT), allowing selling stockholders to r | May 14, 2026 |
| FDMT | EFFECT | neutral | 4/10 | The SEC declared effective 4D Molecular Therapeutics' S-3 shelf registration (File No. 333-295650) on May 13, 2026, allo | May 14, 2026 |
| LNZAW | 8-K | neutral | 4/10 | LanzaTech reported Q1 2026 revenue of $12.0M, roughly in line with the $12.1M consensus, and a net loss of $14.7M, impro | May 14, 2026 |
| TVRD | EFFECT | bearish | 6/10 | Tvardi Therapeutics' S-3 shelf registration (File No. 333-287675) became effective on May 13, 2026. The shelf allows the | May 14, 2026 |
| EDIT | PRESS-RELEASE | bullish | 5/10 | Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction in NHPs durable thro | May 14, 2026 |
| LNZA | PRESS-RELEASE | bullish | 6/10 | LanzaTech reported Q1 2026 EPS of -$1.77, beating consensus of -$2.88 by 38.5%, and revenue of $12.0M (vs $12.1M est, in | May 14, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a 1-for-25 reverse stock split approved by the board on March 16, 2026, effective May 18, 20 | May 13, 2026 |
| MNKD | CLUSTER | neutral | 3/10 | Two insiders at MannKind Corp made open-market sales totaling $66K (0.007% of market cap) on May 12, 2026, one week afte | May 13, 2026 |
| ANIP | CLUSTER | neutral | 4/10 | A cluster of insider sales at ANI Pharmaceuticals, led by CEO Nikhil Lalwani selling $4.27M worth of shares, follows a s | May 13, 2026 |
| ARQT | CLUSTER | neutral | 3/10 | Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including the CFO and three oth | May 13, 2026 |
| MIST | S-3 | bearish | 6/10 | Milestone Pharmaceuticals filed a $300M universal shelf registration (S-3) on May 13, 2026, including a $100M at-the-mar | May 13, 2026 |
| AKAN | 6-K | neutral | 4/10 | Akanda Corp. filed a 6-K announcing a second adjournment of its special shareholder meeting, now scheduled for May 25, 2 | May 13, 2026 |
| INSM | 144 | neutral | 2/10 | Sara Bonstein, an officer of Insmed, filed a Form 144 on May 13, 2026, indicating intent to sell 8,272 shares of common | May 13, 2026 |
| APTOF | 8-K | neutral | 5/10 | Aptose reported Q1 2026 results with a net loss of $7.6M, wider than the $5.5M loss in Q1 2025, as R&D spending increase | May 13, 2026 |
| MRMD | 8-K | neutral | 4/10 | MariMed reported Q1 2026 revenue of $39.5M, up 4.2% YoY from $37.9M, and GAAP net loss narrowed to $3.8M from $5.5M. Adj | May 13, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling | May 13, 2026 |
| ALKS | DEFA14A | neutral | 2/10 | Alkermes filed a DEFA14A on May 13, 2026, sending an email to employees encouraging them to vote their shares ahead of t | May 13, 2026 |
| DYN | 144 | neutral | 2/10 | Director John Cox filed a Form 144 notice of intent to sell 3,311 shares of Dyne Therapeutics common stock, valued at ap | May 13, 2026 |
| DYN | 144 | neutral | 2/10 | Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 1,448 shares of common stock, w | May 13, 2026 |
| RLMD | S-3ASR | bearish | 6/10 | Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, registering an indetermin | May 13, 2026 |
| INSM | CLUSTER | neutral | 3/10 | Insmed's CEO and CMO sold a combined $1.27M in stock within a week of a strong Q1 2026 earnings beat (revenue up 230% Yo | May 13, 2026 |
| GHRS | 6-K | bearish | 6/10 | GH Research filed its 2025 annual report (Form 20-F) via a 6-K, revealing a net loss of $48.3 million (up from $39.0 mil | May 13, 2026 |
| CVM | 8-K | bearish | 7/10 | CEL-SCI Corporation closed a best-efforts public offering of 6,000,000 shares at $1.20 per share, raising $7.2 million i | May 13, 2026 |
| PBH | 8-K | bearish | 7/10 | Prestige Consumer Healthcare reported Q4 FY2026 revenue of $281.6M (down 5.0% YoY) and GAAP diluted EPS of $1.13, missin | May 13, 2026 |
| RVPH | PRESS-RELEASE | bearish | 7/10 | Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/sh | May 13, 2026 |